Men diagnosed with metastatic prostate cancer that lacks the PTEN protein now have a targeted drug option for the first time. The FDA approved capivasertib, sold as Truqap by AstraZeneca, on June 12, 2026, for use alongside abiraterone and prednisone in adults whose tumors are PTEN-deficient and still respond to androgen pathway drugs. The decision rests on the phase III CAPItello-281 trial and a newly cleared companion diagnostic test that will determine which patients qualify.
How PTEN-deficient prostate cancer got its first targeted regimen
PTEN loss is one of the most common genetic alterations in prostate cancer, and it is tied to faster disease progression and weaker responses to standard hormone therapies. Until now, patients with PTEN-deficient metastatic disease received the same treatments as those without the alteration, even though their outcomes were consistently worse. The new approval changes that dynamic by creating a biomarker-driven treatment pathway specifically for this subset.
The FDA’s decision covers a patient population previously described as metastatic hormone-sensitive prostate cancer, now formally labeled metastatic androgen pathway modulation-naive or -sensitive, or mAPMN/S. That updated terminology reflects a broader shift in how regulators classify prostate cancer by treatment history rather than by a single hormone axis. The practical effect: oncologists treating newly diagnosed metastatic disease must now determine PTEN status before choosing a regimen, adding a step that most community practices have not routinely performed.
An Oncologic Drugs Advisory Committee meeting on April 30, 2026, reviewed the benefit-risk profile of capivasertib in this setting. The briefing document prepared for that session examined trial design, statistical methods, and questions about how PTEN deficiency was defined and tested. The agency’s willingness to approve the drug roughly six weeks after that advisory review signals confidence in the evidence package, though the speed also reflects the limited options these patients have faced.
CAPItello-281 trial results and the companion diagnostic
The approval is built on CAPItello-281, a randomized, double-blind phase III trial registered as NCT04493853. The study compared capivasertib plus abiraterone and prednisone against abiraterone and prednisone alone in patients with PTEN-deficient metastatic disease. AstraZeneca’s presentation to the advisory committee framed the PTEN-deficient population as hard to treat and highlighted gains in radiographic progression-free survival as the primary efficacy measure. The supplemental application filed under NDA 218197 s-4 contains the FDA’s own summary of those results, which underpinned the agency’s conclusion that the triplet provides a clinically meaningful delay in disease progression.
Equally significant is the companion diagnostic cleared alongside the drug. The VENTANA PTEN (SP218) RxDx Assay, approved under PMA P250031, is a qualitative immunohistochemistry test that evaluates PTEN protein expression in formalin-fixed, paraffin-embedded prostate tissue. Without this specific assay confirming PTEN loss, a patient does not qualify for the capivasertib regimen under the approved label. That requirement ties the drug’s commercial reach directly to how quickly pathology labs adopt the test and integrate it into routine workflows for metastatic prostate cancer.
The peer-reviewed results of CAPItello-281 have been published in Annals of Oncology, providing the clinical community with a detailed account of endpoints, methods, and the imaging schedule used to assess progression. That publication shows that radiographic progression-free survival favored the capivasertib arm across pre-specified subgroups, including patients with high-volume disease at baseline. For oncologists evaluating whether to prescribe the triplet, the journal article and the FDA’s own summary are the primary references for efficacy and safety data.
Safety findings in CAPItello-281 were generally consistent with the known profiles of AKT inhibition and abiraterone-based therapy. Diarrhea, rash, and hyperglycemia occurred more often with capivasertib, and dose interruptions or reductions were sometimes required to manage these events. Liver function abnormalities and hypertension, already familiar toxicities with abiraterone and prednisone, remained important monitoring priorities. The advisory committee discussion focused on whether these added risks were acceptable in a metastatic but hormone-sensitive population, ultimately concluding that the progression benefit justified the toxicity burden for appropriately selected patients.
From a regulatory standpoint, capivasertib joins a growing list of targeted and immune-based therapies cleared for oncology indications. The FDA’s oncology approval notifications highlight the agency’s emphasis on biomarker-defined subsets, even within common tumor types such as prostate cancer. In that context, PTEN deficiency now functions as a gatekeeper for a specific regimen, similar to how HER2 or PD-L1 status directs treatment choices in breast and lung cancers.
How the new label will change practice
For urologists and medical oncologists, the immediate practical implication is the need to build PTEN testing into the diagnostic workflow. Many newly diagnosed metastatic patients undergo biopsy at community hospitals where molecular pathology resources vary widely. To prescribe capivasertib, clinicians must ensure that tissue samples are sent to a lab that offers the VENTANA assay, understand how results are reported, and interpret those findings in light of the drug’s indication.
The FDA’s detailed summary on capivasertib plus abiraterone underscores that only patients with confirmed PTEN loss are eligible. That makes clear documentation of test results essential in the medical record. It also raises logistical questions about retesting when initial samples are inadequate or when patients present with only small-volume biopsy material from bone metastases, where obtaining high-quality tissue can be challenging.
Cost and access will shape how widely the regimen is used. Capivasertib is an oral targeted agent layered onto an already expensive backbone of abiraterone and chronic prednisone. Insurers are likely to require proof of PTEN deficiency via the approved assay before authorizing coverage, and some may impose step-therapy rules that push patients toward less costly options first. For patients, this could translate into prior authorization delays and paperwork hurdles at precisely the moment when rapid initiation of systemic therapy is clinically important.
Guideline bodies have not yet fully incorporated capivasertib into standard treatment algorithms for metastatic androgen pathway modulation-naive or -sensitive disease. As those updates emerge, they will influence how quickly the regimen becomes a default choice for PTEN-deficient patients versus a niche option reserved for select cases. Academic centers, which tend to adopt new biomarker-driven approaches earlier, may see a faster transition than smaller practices that lack in-house pathology or clinical trial infrastructure.
Gaps in the evidence and what to watch next
Several questions remain open. Mature overall survival data from CAPItello-281 have not yet appeared in the primary FDA documents reviewed for this approval. Radiographic progression-free survival, while clinically meaningful, does not tell patients or their doctors whether the drug extends life. Regulators sometimes grant approval on the strength of progression endpoints and require post-marketing data to confirm a survival benefit, and that pattern appears to apply here. Future updates from the trial will need to show whether delaying progression ultimately translates into longer survival or better quality of life.
Real-world PTEN testing rates are another blind spot. The VENTANA assay is now cleared, but how many pathology labs currently run it, how long turnaround takes, and whether insurers will cover the test without friction are all unanswered. If adoption is slow, the approval could remain largely academic for patients treated at community oncology practices that lack immediate access to the assay. The hypothesis that routine IHC testing for PTEN will become standard in new metastatic prostate cancer workups within a year depends on lab infrastructure, reimbursement decisions, and clinical guideline updates that have not yet been issued.
Post-marketing safety surveillance will also be important. The combination of an AKT inhibitor with long-term steroid use raises theoretical concerns about metabolic complications, infection risk, and cardiovascular events in an older male population already burdened with comorbidities. The FDA’s oncology division routinely monitors adverse event reports and may request additional risk mitigation measures if new safety signals emerge once capivasertib is used more broadly outside of clinical trials.
For patients and caregivers, the immediate step is straightforward: anyone diagnosed with metastatic prostate cancer that has not yet been treated with androgen pathway drugs should ask whether PTEN testing has been performed on their tumor tissue. The FDA’s page on this new approval outlines who is eligible and how the drug is meant to be used. As oncologists and pathologists adapt to the new requirements, the hope is that PTEN status will become as routine a part of metastatic prostate cancer evaluation as PSA levels and imaging, ensuring that patients who stand to benefit from capivasertib actually receive it.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
